# US 11,999,783 B2 · Method of treating autoimmune disease with antibodies against IL-33

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,783 B2
- Document ID: US11999783B2
- Status: Granted
- Kind: B2
- Application number: 17/071,046
- Filed: 2020-10-15
- Published: 2021-02-11
- Granted: 2024-06-04
- Earliest claimed: 2014-01-10
- Assignees: AnaptysBio, Inc.
- Applicants: AnaptysBio, Inc.
- Inventors: Robert A. Horlick; David J. King; Andrew John McKnight
- Web page: https://patentgrep.com/patent/US11999783B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

## Claims

### Claim 1

A method of treating an autoimmune disease using an interleukin-33 (IL-33) binding protein comprising an immunoglobulin heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 136, and an immunoglobulin light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 171.

### Claim 2 (depends on 1)

The method of claim 1, wherein the autoimmune disease is Crohn's disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the autoimmune disease is rheumatoid arthritis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the autoimmune disease is psoriasis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the autoimmune disease is ankylosing spondylitis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the autoimmune disease is lupus erythematosus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the autoimmune disease is scleroderma.

### Claim 8 (depends on 1)

The method of claim 1, wherein the IL-33 binding protein is an antibody, an antibody conjugate, or an antigen-binding fragment thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the IL-33 binding protein is a F(ab′)2, Fab′, Fab, Fv, scFv, dsFv, dAb, or a single chain binding polypeptide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the half-life of the IL-33 binding protein is between 30 minutes and 45 days.

### Claim 11 (depends on 1)

The method of claim 1, wherein the IL-33 binding protein binds to IL-33 with a KD less than or equal to 1 nanomolar.

### Claim 12 (depends on 1)

The method of claim 1, wherein the IL-33 binding protein is an IgG1 antibody.